Warren Lammert is a co-founder and serves as the Chairman of Tevard Biosciences. He has over 35 years of public and private investment experience and is the founder and Chief Investment Officer of Granite Point Capital, a Boston based investment firm with over $300 million in assets that invests in both public and private companies. Warren has worked extensively to support new therapies in epilepsy.
He is the co-founder of Epilepsy.com and the Epilepsy Therapy Project, a past Chairman of the Epilepsy Foundation and is a current member of the advisory board of Finding a Cure for Epilepsy and Seizures at NYU. Warren has served in board roles with companies including Biscayne Neurotherapeutics (acquired by Supernus Pharma in 2018), Engage Therapeutics (acquired by UCB in 2020) and Cerebral Therapeutics. Warren is a graduate of Yale University and the London School of Economics where he completed an MSC in Economic History with Distinction and is a CFA® charterholder.